Emergent BioSolutions (EBS) Invested Capital (2010 - 2020)

Emergent BioSolutions' Invested Capital history runs 7 years deep, the most recent figure standing at $22.3 million for Q2 2020.

• On a quarterly basis, Invested Capital fell 59.16% year-over-year to $22.3 million in Q2 2020; TTM through Mar 2021 was $22.3 million, a 80.35% decrease from a year earlier, with the FY2019 full-year figure at $3.2 million, down 42.86% from the prior year.
• Invested Capital grew to $22.3 million in Q2 2020 per EBS's latest filing, from $3.2 million in the prior quarter.
• Across five years, Invested Capital topped out at $62.7 million in Q1 2019 and bottomed at $3.2 million in Q4 2019.
• The 3-year median for Invested Capital is $38.4 million (2019), against an average of $34.0 million.
• Across the five-year window, Invested Capital slumped 42.86% in 2019 and slumped 59.16% in 2020, its largest moves.
• Year by year, Invested Capital stood at $5.6 million in 2018, then tumbled by 42.86% to $3.2 million in 2019, then soared by 596.88% to $22.3 million in 2020.
• Per Business Quant, the three latest EBS Invested Capital figures stand at $22.3 million (Q2 2020), $3.2 million (Q4 2019), and $55.7 million (Q3 2019).